Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT06913725
An Exploratory Study to Evaluate the Efficacy and Safety of FCN-159 in Patients With Brain Arteriovenous Malformations
Sponsor: Shanghai Fosun Pharmaceutical Industry Development Co., Ltd
Conditions
Brain Arteriovenous Malformations
Interventions
FCN-159
Updated 1 time since 2025 Last updated: Mar 30, 2025 Started: Feb 24, 2025 Primary completion: Mar 31, 2026 Completion: Sep 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Brain Arteriovenous Malformations and is currently actively recruiting participants. Shanghai Fosun Pharmaceutical Industry Development Co., Ltd leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Shanghai Fosun Pharmaceutical Industry Development Co., Ltd
- Xuanwu Hospital, Beijing
Data source: Xuanwu Hospital, Beijing
For direct contact, visit the study record on ClinicalTrials.gov .